Vasogen Provides Update on ACCLAIM II Program

    MISSISSAUGA, ON, March 3 /CNW/ - Vasogen Inc. (NASDAQ:  VSGN; TSX:VAS)
today provided an update on ACCLAIM II, a clinical trial which is being
planned to support an application for U.S. market approval of the Celacade(TM)
System for the treatment of patients with New York Heart Association (NYHA)
Class II heart failure.
    The Company announced in December that the FDA was examining its internal
jurisdiction over Vasogen's Celacade System in the context of a newly issued
draft guidance document to assess whether this document was relevant to
Celacade. Previously, the FDA's Center for Devices and Radiological Health
(CDRH) acted as lead reviewer of Celacade, with input from the Center for
Biologics Evaluation and Research (CBER). The FDA has confirmed that Celacade
will remain regulated as a medical device; however, CBER will be the lead
reviewer of the Celacade technology, with CDRH providing input. The transition
process from CDRH to CBER is now complete.
    As part of the transition, on February 29, CDRH communicated to the
Company that they now disagree with the use of a Bayesian approach because of
a concern with recruiting a heterogeneous study population between ACCLAIM and
ACCLAIM II. This is contrary to the FDA's original communication to Vasogen
recommending a Bayesian study design, and, as part of its ongoing informal
dialogue, the Company plans to provide the FDA with its position regarding the
ACCLAIM II study population.
    "The FDA's comments with respect to utilizing a Bayesian approach for the
design of ACCLAIM II are surprising," commented Chris Waddick, President and
CEO of Vasogen. "Our immediate focus will be to engage in discussions with the
FDA to clarify their position on the proposed ACCLAIM II study protocol and
statistical analysis plan and to work with members of the ACCLAIM II Steering
Committee and our statistical advisors to address the FDA's concerns. We will
provide an update to shareholders once we have had further discussions with
the FDA."
    Vasogen retained Berry Consultants and Dr. Donald A. Berry, Head,
Division of Quantitative Sciences and Chairman, Department of Biostatistics,
The University of Texas MD Anderson Cancer Center, and a world recognized
authority in the area of Bayesian and adaptive trial design. Dr. Berry has
been assisting Vasogen throughout the development of ACCLAIM II study design.
Vasogen has also established the ACCLAIM II Steering Committee led by James B.
Young, MD, Chairman, Division of Medicine at the Cleveland Clinic Foundation
and Medical Director, Kaufman Center for Heart Failure, appointed Chairs for
the Data and Safety Monitoring Board (DSMB) and Central Endpoint Committee
(CEC), and has drafted the key trial documents necessary to initiate the
trial. The Company has also selected a CRO and has identified and received
commitments from U.S.-based clinical sites to participate in the study. The
majority of these sites participated in the first ACCLAIM trial and were
selected on the basis of their ability to quickly recruit patients and conduct
high quality research.

    About Vasogen:

    Vasogen is a biotechnology company engaged in the research and commercial
development of therapies designed to target the destructive inflammatory
process associated with the development and progression of cardiovascular and
neurodegenerative disorders. The Company's lead product, the Celacade(TM)
System, is designed to activate the immune response to apoptosis - an
important physiological process that regulates inflammation. Celacade has
received European regulatory approval under the CE Mark for chronic heart
failure and is being marketed in the EU by Grupo Ferrer Internacional, S.A.
Celacade is also in late-stage clinical development for the treatment of
chronic heart failure in the United States. Vasogen is also developing a new
class of drugs for the treatment of certain neuro-inflammatory disorders.
VP025 is the lead candidate from this new class of drugs.

    Certain statements contained in this press release, or elsewhere in our
public documents constitute "forward-looking statements" within the meaning of
the United States Private Securities Litigation Reform Act of 1995 and/or
"forward-looking information" under the Securities Act (Ontario). These
statements may include, without limitation, plans to advance the development
of Celacade(TM) or VP025, plans to fund our current activities, statements
concerning our partnering activities, health regulatory submissions, strategy,
future operations, future financial position, future revenues and projected
costs. In some cases, you can identify forward-looking statements by
terminology such as "may", "will", "should", "expects", "plans",
"anticipates", "believes", "estimated", "predicts", "potential", "continue",
"intends", "could", or the negative of such terms or other comparable
terminology. We made a number of assumptions in the preparation of these
forward-looking statements, including assumptions about the nature, size, and
accessibility of the market for Celacade in the treatment of chronic heart
failure, particularly in Europe, the regulatory approval process leading to
commercialization and the availability of capital on acceptable terms to
pursue the development of Celacade, and the feasibility of additional trials.
You should not place undue reliance on our forward-looking statements which
are subject to a multitude of risks and uncertainties that could cause actual
results, future circumstances or events to differ materially from those
projected. These risks include, but are not limited to, the outcome of further
ongoing analysis of the ACCLAIM trial results, the requirement or election to
conduct additional clinical trials and the size and design of any such trials,
delays or setbacks in the regulatory approval process, difficulties in the
maintenance of existing regulatory approvals, securing and maintaining
corporate alliances, the need for additional capital and the effect of capital
market conditions and other factors on capital availability, the potential
dilutive effects of any financing, risks associated with the outcomes of our
preclinical and clinical research and development programs, the adequacy,
timing, and results of our clinical trials, competition, market acceptance of
our products, the availability of government and insurance reimbursements for
our products, the strength of intellectual property, reliance on partners,
subcontractors, and key personnel, losses due to fluctuations in the
U.S.-Canadian exchange rate, and other risks detailed from time to time in our
public disclosure documents or other filings with the Canadian and U.S.
securities commissions or other securities regulatory bodies. Additional risks
and uncertainties relating to our Company and our business can be found in the
"Risk Factors" section of our Annual Information Form and Form 20-F for the
year ended November 30, 2007, as well as in our later public filings. The
forward-looking statements are made as of the date hereof, and we disclaim any
intention and have no obligation or responsibility, except as required by law,
to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

    %SEDAR: 00001047E          %CIK: 0001042018

For further information:

For further information: Glenn Neumann, Investor Relations, 2505
Meadowvale Blvd., Mississauga, ON, Canada, L5N 5S2, tel: (905) 817-2004, fax:
(905) 569-9231,,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890